AI Startups
| Name | Introduction |
| AInvest | AInvest是一家开发投资领域人工智能的先锋金融科技公司。通过机器学习、大数据和云计算的结合，我们致力于开发一个能够实现自我进化、剖析海量数据的蝴蝶效应的全自动投资AI，帮助投资者更准确、快速、高效地做出明智的投资决策。AInvest与券商、资产管理公司、投资顾问和新闻平台合作，提供人工智能投资分析师- alpha刀。该AI机器人能够提供股票选择、动态资产配置、市场择时、自动交易、自动撰写股票报告、基于云计算的深度数据挖掘以及其他AI定制服务。
AInvest is a pioneer of implementing artificial intelligence technology in investment processes through a combination of machine learning, big data and cloud computing. We are committed to develop a A.I. based self-evolving automatic investment system, to help investors make smart investment decisions more accurately, quickly and efficiently.AInvest has partnered with brokers, asset managers, financial advisors and news platforms to offer AI investment analyst – alphaDao. This AI robot is capable of providing stock selection, dynamic asset allocation, market timing, automatic trading, writing stock reports, cloud-based in-depth data mining and other customized AI services. |
| BrainRobotics | BrainRobotics is currently developing high performance smart prosthetic hands and is aiming to lower the traditional prosthetic price an order of magnitude to $3,000. The BrainRobotics team is comprised of engineers from MIT and other top universities. We currently focus on developing the next generation electromyography controlled smart prostheses. With BrainRobotics’ technology, people are in control to live a wonderful life. The BrainRobotics team develops advanced machine learning algorithms and utilizes multi-channel muscle signal detection devices to allow amputees to intuitively control our prosthetic hands. Traditional prostheses have an integrated design that is vulnerable to damage. To solve this problem, our team is working on a modular mechanical design. It allows users to easily replace only the broken components without having to purchase an entirely new hand. Such modular designs will significantly reduce the cost of using prosthetic hands. Our team is also applying 3D scanning and printing technologies to make sockets that accommodate individual differences. Such designs allow for seamless contact between the sensors within the socket and the residual limb for high performance signal detection. Such personalized designs also allow added comfortability for amputees to wear our prostheses for longer periods of time. |
| Labby | Labby is an AI-Powered Food Testing and Analytics Platform. Our mission is to eliminate avoidable food loss in the supply chain and increase transparency and trust in the food system. We are providing value in the dairy industry by enabling instant farm level testing of milk to maximize quality for farmers and minimize procurement risks for dairy companies. |
| MirrorAI | MirrorAI 以人工智能领域情绪识别为主要技术研发核心，联合美国麻省理工、以色列理工等技术专家资源，打造于在线教育、 在线购物、公共安全、自动驾驶等领域的产业链商业服务和应用。基于强大的神经网络与人脸识别算法，MirrorAI 实现了对人脸表情情绪及相关属性的识别分析。该技术已经实现了对包括开心、哀伤、生气、困惑在内的 11 种人脸表情情绪识别。MirrorAI针对在线教育的用戶痛点“退课率高、用戶粘性低 、学生与教师之间的互动不及时”，创立了第一个于在线教育产业链的应用项目DiscoveryAI.org，欲通过识别学生在课堂的实时情绪表情变化，分析出参与课堂的积极程度，并在后台提供及时的辅助学习响应，建立起学生与教师间有效互动的桥梁。
MirrorAI is an artificial intelligence startup focusing on emotion recognition. With the expertise resources from MIT, Technion, etc, MirrorAI aims to build industrial and commercial applications of emotion recognition in areas such as online education, online shopping, public safety and driving alert. Based on solid neural networks and face recognition algorithms, MirrorAI fulfills top-level analysis accuracy in the industry. Our technology can precisely recognize more than 10 emotions real time including happiness, sadness, anger, confusion, etc. MirrorAI has launched the first application on online education, DiscoveryAI.org, which intends to solve the problem of low retention of online study and to construct the real-time effective communication between teachers and students. The methods DiscoveryAI applies are to analyze the emotional changes of students in class and provide complementary backend response on time to involve students to be active learners. |
| Name | Introduction |
| Cignifi | Cignifi Inc. is an end-to-end data analytic platform that ingests mobile data and delivers behavioral insight scores used for cash loans, handset loans, and airtime credit. |
| Crypto Smart Beta | We are Crypto Smart Beta, the world’s first smart beta based, quantitative crypto mutual fund. Our founder is leading the market neutral equity arm of a multi-hundred-million quantitative hedge fund. Our team boasts experienced partners in quant research / trading / technology and crypto article searching / reviewing / recommendations. Our website is cryptosmartbeta.com.
We seek to optimize the production relations in two highly centralized areas: peer-reviewed publishing and crypto asset management. 1. We publish peer-reviewed crypto analysis in both academic and pop science domains, compensate authors, reviewers and editors for their work, and share half of subscription proceeds with all authors. Subscriptions to our publications and compensations will be paid in our tokens (BETA). The subscription service is offered for both articles and data (if applicable). 2. All our strategies are posted in great details on our website, which are mostly transparent risk premiums (smart beta). We charge 2% management fee for the advisory and trading service. No incentive fee for the main book, but selected strategies with alpha nature might incur an incentive fee. We share a generous cut with referenced strategy / analysis authors, up to half of the management fee if they co-manage the book with us. 我们是Crypto Smart Beta，全球第一家基于数字货币智能贝塔的量化共同基金。我们的创始人在一家数亿美元规模的量化对冲基金主管全球股市市场中性策略。团队合伙人包括经验丰富的量化研究/交易员，企业高管CTO和长于数字货币文章约稿、评审、推荐的专家。我们的网站是cryptosmartbeta.com。 我们寻求在以下两个高度中心化的领域改进现有的生产关系：基于同行评审的文章出版和数字货币资产管理。1. 我们发表通过同行评议的、学术和科普性质的数字货币分析，向作者、审稿人和编辑支付报酬并与作者分享一半的订阅费用，一切都通过我们发行的BETA通证支付。订阅服务适用于网站发表的文章或者数据。2. 我们的交易策略大多数基于公开透明的风险溢价（智能贝塔），并全部在网站上以论文的形式详细介绍。我们提供咨询和交易服务并在主基金收取2%的年管理费，无任何表现费。某些具有阿尔法性质的次级基金可能同时收取表现费。我们向被引用的策略或量化分析作者慷慨地分成管理费，在共同管理投资组合的情况下最多可达一半。 |
| Cypherium | Lead blockchain cryptographers have banded together with experts from companies such as Google, Amazon & Microsoft to create Cypherium. Building off Emin Gun Sirer and Bryan Ford’s work on the Bitcoin-NG and ByzCoin protocols, Cypherium aims to be a market-ready solution for scalability. Cypherium is comprised of experienced technologists possessing extensive background in cryptography, decentralized networking and software architecture.
Cypherium will be leveraging a hybrid PBFT/PoW consensus mechanism to provide optimal on-chain scalability, enabling thousands of transactions per second. This novel consensus mechanism adopts the idea of decoupling key block mining from micro blocks for faster transaction processing, first pioneered in Bitcoin-NG. Cypherium also borrows from ByzCoin to elect a group of validators from recent key block miners, ultimately allowing said groups to commit transactions collectively. Additionally, Cypherium has a light-weight sandbox environment that separates testing and production, while supporting consensus self-upgrades. By bringing governance on chain, Cypherium will avoid hard-forks and ultimately allow network participants to adaptively adjust transaction block sizes as well as other proposed protocol upgrades. |
| iComplyICO | iComplyICO is an all-in-one platform that expertly guides you through the steps of launching your ICO (Initial Coin Offering) or token sale. |
| Hellofriend | Hellofriend is a blockchain-based platform that allows people to buy and sell social experiences around the globe. With a team of Harvard and MIT students, Hellofriend is currently based at the Harvard Innovation Lab. |
| Inkrypt | Inkrypt is a Harvard Innovation Labs based venture that focuses on becoming the Web 3.0 solution for journalism. It is building a censorship-resistant global distributed nodal network, timestamped using a blockchain ledger, that provides content storage and distribution for journalism outlets. The distributed nature of the network coupled with a content-adrxessing will provide reliable, fast and secure content hosting with both front and back-end censorship resistance, helping make journalism truly free. |
| OneGame | One Game is the world’s first blockchain-based self-evolving VR platform. It provides a set of easy to use, yet powerful tools, to allow anyone to create their own virtual world. As a decentralized platform, One Game grants gamers voting power and governance over its realm, as well as a tokenized economy that rewards top performing creators and players. By applying the theory of genetic combination and selection, the game AI and varied elements within the platform will cross breed and evolve over time.
One Game team is comprised of world class engineers and game developers with experience working for some of the world’s most noteworthy tech companies, including Google and Microsoft. 万世（OneGame）是搭建在区块链上的去中心化的虚拟世界。它是一款沙盒游戏，同时也是一个游戏的制作和分发平台。万世通过简单易用但功能强大的工具，允许玩家购买土地并开发属于自己的游戏场景，并通过区块链上的代币经济系统，对平台上排名靠前的开发者和玩家进行虚拟的挖矿奖励。在这里，玩家就是上帝，平台中的所有重要决策都由玩家组成的委员会投票决定。最后，万世是一个自我进化的系统，在这里，每一个角色都与DNA绑定，新的角色通过基因的组合、选择和变异，源源不断的被生成。万世目前和深脑链，路印等国内著名区块链项目都有合作。 |
| WishKnish | WishKnish offers businesses, affiliates, and non-profits a decentralized marketplace platform for launching gamified, socially-engaged storefront communities equipped with the tools to turn regular users into super-fans and evangelizers while streamlining coin-agnostic e-commerce and fulfillment, as well as offering advanced blockchain-as-a-service tools to meet enterprise clients’ needs. WishKnish began launching its first beta storefronts in the Fall of 2017. |
Biotech Startups
| Name | Introduction |
| BiomaRx | Based out of Cambridge, MA, BiomaRx is a venture focused on making many deadly cancers treatable condition through early diagnosis. The team is developing non-invasive diagnostics for early detection of cancer with the initial focus on pancreatic cancer, a disease that is projected to be the second leading cancer killer by 2020. Spun out of Harvard Medical School and Beth Israel Deaconess Medical Center, BiomaRx uses a proprietary systems biology engine to identify next-gen diagnostic biomarkers and therapeutic targets for first-in class diagnosis and treatment. |
| Insignis Pharmaceuticals | Insignis Pharmaceuticals is a leader in formulation and generic drug development. The company has experience and history in the development and manufacturing of multiple difficult-to-develop formulations including nasal sprays, semi-solids and extended release solids. Multiple ANDA generic products were developed by the team and approved by the US FDA. Currently there are multiple ANDA products under development: INS-1: Anti-viral ointment INS-2: Extended release tab for schizophrenia, mania or depressions INS-3: Local pain relief ointment INS-4:Extended release tab for neuropathic pain caused by diabetes/HPV, Fibromyalgia INS-5: Arthritis INS-6: Anti-cancer |
| Octagon Therapeutics | Octagon was founded on a novel drug discovery technology invented at Harvard. Both inventors have joined the founding team. The foundational discovery platfrom enables Octagon to identify novel antibiotics that are effective against multidrug resistant superbugs. One medicine identified, OTG005, has shown compelling efficacy in animal infection models of Gram negative infection. These models are unique in that they possess a high level of predictive power for human efficacy. OTG005 additionally has an established human safety profile, and can therefore be rapidly advanced into clinical validation.
Octagon is in the process of exploring chemical analogs of OTG005, which might be additional high-value antibiotics. The company is building relationships with large partners and anticipates out-licensing antibiotic candidates after early clinical validation. The company has exclusive access to the intellectual property generated at Harvard/MGH. Octagon has retained a powerful Scientific Advisory Board, including MIT luminary Jim Collins. The company started operations in 2017, and currently resides in state-of-the-art lab space at the Pagliuca Life Lab. Octagon is funded by angel investors and family offices, and has currently closed 1.6M of a target 2M financing round to support preclinical development and IND-submission. |
| Panacea | Panacea is a smart oral care device that cleans and whitens teeth in 10 seconds. It uses sonic vibration and novel bite pad to reduce bacteria level and makes tooth brushing experience more pleasant. It has special toothpaste delivered to users under subscription model. It will collect users’ data on biting strength etc., analyze it and report to dentist. The manufacturing cost is under $20 for the device. Prototypes are in beta testing phrase, currently in contact manufacturers |
| Raiing | Raiing Medical was founded in 2011 in Beijing and incorporated in United States in 2014. We provide clinical grade wearables for vital signs monitoring and AI solutions of health data service based on IoT platform, enabling precision medicine at individual level for disease diagnosis, management, prediction and prevention. Our solution is clinical validated with publication and offers seamless communication for connected health in both inpatient and outpatient settings. Our product is FDA 510(k), CFDA and CE cleared with sales of double digits CAGR. We have 35 employees in Beijing, 5 in Boston and 1 in London. Our management team has diversified background of medical device, digital health, R & D, manufacturing, sourcing, and fast moving consumer goods. We have raised $8 million from previous rounds and are seeking for $10m for round B fundraising. We are Raiing Medical, connected health for tomorrow. |
| Vibronix | Vibronix was cofounded by Moustakas Professor, Dr. Ji-Xin Cheng at Boston University, and Dr. Pu Wang (Young 1000 talents program) at Beihang University in 2014. Vibronix is developing advanced imaging and sensing technologies to improve diagnosis and treatment of diseases. Currently, Vibronix focuses on development and commercialization of photoacoustic technologies. Based on its proprietary technologies in miniaturized photoacoustic probe, laser design and optical-acoustic navigation, Vibronix has developed several innovative medical devices including: intraoperative margin assessment tool for breast cancer surgery (MarginPAT), navigation system for percutaneous nephrolithotomy (AcouSEE), and intravascular photoacoustic imaging (IVPA) for cardiovascular disease. |